[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Gains As Market Dips: What You Should Know",
    "summary": "The latest trading day saw AbbVie (ABBV) settling at $191.50, representing a +1.06% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=eac3ecee9c8483cb037a9a61866b3bb793ffb9d20238325b7716964de99203cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749678306,
      "headline": "AbbVie (ABBV) Gains As Market Dips: What You Should Know",
      "id": 135201298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The latest trading day saw AbbVie (ABBV) settling at $191.50, representing a +1.06% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=eac3ecee9c8483cb037a9a61866b3bb793ffb9d20238325b7716964de99203cf"
    }
  },
  {
    "ts": null,
    "headline": "FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)",
    "summary": "Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis or with compensated cirrhosis. Glecaprevir, one of the two DAAs in Mavyret, was Discovered by Enanta Pharmaceuticals, Inc (NASDAQ:",
    "url": "https://finnhub.io/api/news?id=c98f4ea2061fb37a4e743dfa575c565fe1b09efc5a064cdca2625be0eb6e8861",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749676038,
      "headline": "FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)",
      "id": 135201300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis or with compensated cirrhosis. Glecaprevir, one of the two DAAs in Mavyret, was Discovered by Enanta Pharmaceuticals, Inc (NASDAQ:",
      "url": "https://finnhub.io/api/news?id=c98f4ea2061fb37a4e743dfa575c565fe1b09efc5a064cdca2625be0eb6e8861"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET速 (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus",
    "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET速 (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. With this approval, MAVYRET is the first and only DAA therapy approved to treat patients w",
    "url": "https://finnhub.io/api/news?id=43741cfb94132a9becb1bc8cd1d798471ae10dfae71a4a691b79b19800dfa962",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749659460,
      "headline": "U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET速 (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus",
      "id": 135201301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET速 (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. With this approval, MAVYRET is the first and only DAA therapy approved to treat patients w",
      "url": "https://finnhub.io/api/news?id=43741cfb94132a9becb1bc8cd1d798471ae10dfae71a4a691b79b19800dfa962"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=d450ebe99b0a76c9268fad9c3ff1aa4c4de8240834913fe07a9b3d44b789f1cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749646805,
      "headline": "Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock",
      "id": 135186427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=d450ebe99b0a76c9268fad9c3ff1aa4c4de8240834913fe07a9b3d44b789f1cb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript",
    "summary": "AbbVie Inc. (NYSE:ABBV) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ETCompany ParticipantsJeffrey Ryan Stewart - Executive...",
    "url": "https://finnhub.io/api/news?id=bf4226d0c83760c3c01a9f3de6e7033437b6ea3ccb57270a1d521af898732cbe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749605779,
      "headline": "AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript",
      "id": 135174397,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. (NYSE:ABBV) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ETCompany ParticipantsJeffrey Ryan Stewart - Executive...",
      "url": "https://finnhub.io/api/news?id=bf4226d0c83760c3c01a9f3de6e7033437b6ea3ccb57270a1d521af898732cbe"
    }
  }
]